Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TNKS | O95271 | 5/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.55 |
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18647351 | 0.91 | MEN1 (0.53) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL18646829 | 0.84 | TNKS (0.59) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL18647418 | 0.83 | TNKS (0.58) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL18646824 | 0.83 | TNKS (0.54) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL18646713 | 0.82 | TNKS (0.53) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL8049657 | 0.80 | MAPT (0.56) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL18774624 | 0.80 | MAPT (0.70) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL24701633 | 0.79 | MAPT (0.63) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL8654364 | 0.77 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ATNKS | |
| SCHEMBL30363482 | 0.77 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1784186-A4 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1784186-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | Inotek Pharmaceuticals Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| WO-2005082368-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004078712-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | MEN1 4630/4885KMT2A 2948/4885MAPT 2186/4885 |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | MEN1 3084/4885KMT2A 2068/4885MAPT 1261/4885 |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | MEN1 2655/4885KMT2A 2285/4885MAPT 1291/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | MEN1 2655/4885KMT2A 2285/4885MAPT 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.